The rising prevalence of Aspergillosis, as well as favourable government policies, are pushing the Aspergillosis treatments market. According to a study published in the Journal of Fungi in 2016, CPA affects about three million individuals worldwide, making it a major public health issue that causes mortality and morbidity. Antifungal and corticosteroid medications can be used to treat aspergillosis. Corticosteroid medications are used to treat allergic bronchopulmonary aspergillosis. These medications help to lessen inflammation and respiratory symptoms including coughing and wheezing. Methylprednisolone, prednisolone, and prednisone are some of the most commonly used medications. Various medications for the Aspergillosis treatments Market infection have been approved by the US Food and Drug Administration (FDA). In 2015, the US Food and Drug Administration approved Isavuconazonium (Astellas Pharma), a prodrug version of Isavuconazole. Invasive pulmonary Aspergillosis is commonly treated with antifungal medications.
Read More: https://www.coherentmarketinsights.com/ongoing-insight/aspergillosis-treatment-market-1587
